Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Protirelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR known ✓ | P34981 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Protirelin SCHEMBL10087855 | 1.00 | TRHR (1.00) | TRHR | |
| Protirelin SCHEMBL10087946 | 1.00 | TRHR (1.00) | TRHR | |
| Protirelin SCHEMBL33419 | 1.00 | TRHR (1.00) | TRHR | |
| Protirelin SCHEMBL4406163 | 0.97 | TRHR (0.93) | TRHR | |
| Protirelin SCHEMBL1007386 | 0.95 | TRHR (0.91) | TRHR | |
| SCHEMBL29539733 | 0.92 | TRHR (0.85) | TRHR | |
| Azetirelin SCHEMBL195158 | 0.92 | TRHR (0.85) | TRHR | |
| Protirelin SCHEMBL11309963 | 0.92 | TRHR (0.84) | TRHR | |
| SCHEMBL16072685 | 0.91 | TRHR (0.84) | TRHR | |
| SCHEMBL16088505 | 0.91 | TRHR (0.84) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9849160-B2 | Methods and systems for treating or preventing cancer | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20140271935-A1 | METHODS AND SYSTEMS FOR TREATING OR PREVENTING CANCER | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271935-A1 | METHODS AND SYSTEMS FOR TREATING OR PREVENTING CANCER | GNRHR, TRHR, LHCGR | TRHR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.